loading page

Dasatinib-induced pulmonary arterial hypertension in pediatric acute lymphoblastic leukemia with Philadelphia chromosome: A report of two cases
  • +8
  • Sujie Tang,
  • hao xiong,
  • Zhi Chen,
  • Li Yang,
  • Ming Sun,
  • Wenjie Lu,
  • Zhuo Wang,
  • Fang Tao,
  • Min Wu,
  • Linlin Luo,
  • Zuofeng Li
Sujie Tang
Jianghan University School of Medicine
Author Profile
hao xiong
Wuhan Children’s Hospital (Wuhan Maternal and Child Healthcare Hospital

Corresponding Author:[email protected]

Author Profile
Zhi Chen
Wuhan Children’s Hospital (Wuhan Maternal and Child Healthcare Hospital
Author Profile
Li Yang
Wuhan Children’s Hospital (Wuhan Maternal and Child Healthcare Hospital
Author Profile
Ming Sun
Wuhan Children’s Hospital (Wuhan Maternal and Child Healthcare Hospital
Author Profile
Wenjie Lu
Wuhan Children’s Hospital (Wuhan Maternal and Child Healthcare Hospital
Author Profile
Zhuo Wang
Wuhan Children’s Hospital (Wuhan Maternal and Child Healthcare Hospital
Author Profile
Fang Tao
Wuhan Children’s Hospital (Wuhan Maternal and Child Healthcare Hospital
Author Profile
Min Wu
Wuhan Children’s Hospital (Wuhan Maternal and Child Healthcare Hospital
Author Profile
Linlin Luo
Jianghan University School of Medicine
Author Profile
Zuofeng Li
Wuhan University of Science and Technology School of Medicine
Author Profile

Abstract

Background: Long-term oral dasatinib administration can induce pulmonary arterial hypertension (PAH) in pediatric patients with Philadelphia chromosome-positive (Ph +) acute lymphoblastic leukemia (ALL). We describe the findings in two pediatric cases involving Ph + ALL patients who developed cardiovascular events such as PAH after dasatinib treatment, and present a review of the related literature. Case presentation: Two pediatric patients diagnosed with B-cell ALL ( BCR-ABL P190 fusion gene positive) received conventional chemotherapy and imatinib simultaneously, which was then changed to dasatinib because of a partial response. The two patients developed PAH after 18 months and 6 years of dasatinib therapy. All signs and symptoms improved after immediate discontinuation of dasatinib and symptomatic treatment. Conclusions: Pediatric Ph + ALL patients receiving dasatinib should be carefully monitored for serious cardiopulmonary and vascular events such as PAH. Development of adverse reactions should be followed by immediate and permanent discontinuation of oral dasatinib. Dynamic monitoring by echocardiography is recommended when administering dasatinib for maintenance therapy.
29 Nov 2022Submission Checks Completed
29 Nov 2022Assigned to Editor
29 Nov 2022Submitted to Pediatric Blood & Cancer
30 Nov 2022Review(s) Completed, Editorial Evaluation Pending
02 Dec 2022Reviewer(s) Assigned
18 Dec 2022Editorial Decision: Revise Major
20 Mar 20231st Revision Received
20 Mar 2023Submission Checks Completed
20 Mar 2023Assigned to Editor
20 Mar 2023Review(s) Completed, Editorial Evaluation Pending
20 Mar 2023Editorial Decision: Accept